Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 322

1.

Correction to: Phase II study of weekly carboplatin in pretreated adult malignant gliomas.

Villani V, Pace A, Vidiri A, Tanzilli A, Sperati F, Terrenato I, Carosi M, Casini B, Metro G, Maschio M, Koudriavtseva T, Cognetti F, Fabi A.

J Neurooncol. 2019 Sep 9. doi: 10.1007/s11060-019-03285-x. [Epub ahead of print]

PMID:
31502041
2.

Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases.

Cortinovis D, Chiari R, Catino A, Grossi F, DE Marinis F, Sperandi F, Piantedosi F, Vitali M, Parra HJS, Migliorino MR, Tondini C, Tassinari D, Frassoldati A, Verderame F, Pazzola A, Cognetti F, Palmiotti G, Marchetti P, Santoro A, Giannarelli D, Colonese F, Delmonte A.

Anticancer Res. 2019 Aug;39(8):4265-4271. doi: 10.21873/anticanres.13590.

PMID:
31366516
3.

Phase II study of weekly carboplatin in pretreated adult malignant gliomas.

Villani V, Pace A, Vidiri A, Tanzilli A, Sperati F, Terrenato I, Mariantonia C, Casini B, Metro G, Maschio M, Tatiana K, Cognetti F, Fabi A.

J Neurooncol. 2019 Aug;144(1):211-216. doi: 10.1007/s11060-019-03223-x. Epub 2019 Jul 4. Erratum in: J Neurooncol. 2019 Sep 9;:.

PMID:
31273578
4.

Advances in Tumor-Stroma Interactions: Emerging Role of Cytokine Network in Colorectal and Pancreatic Cancer.

Bazzichetto C, Conciatori F, Falcone I, Cognetti F, Milella M, Ciuffreda L.

J Oncol. 2019 May 5;2019:5373580. doi: 10.1155/2019/5373580. eCollection 2019. Review.

5.

The unmet need for oncofertility preservation in women: Results of a survey by different oncological specialists in Lazio, Italy.

Fabi A, Lanzetta G, Vizza E, Corsi D, Moscetti L, Spinelli G, Mentuccia L, Lalle M, Perrone M, Baiocco L, Falcicchio C, Milani A, Giannarelli D, Cognetti F, Pugliese P.

Curr Probl Cancer. 2019 May 17. pii: S0147-0272(18)30341-6. doi: 10.1016/j.currproblcancer.2019.05.002. [Epub ahead of print]

PMID:
31126661
6.

Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.

Daniele G, Arenare L, Scambia G, Pisano C, Sorio R, Breda E, De Placido S, Savarese A, Ferrandina G, Raspagliesi F, Panici PB, Ferro A, Rimanti A, Cormio G, Lorusso D, Cecere SC, Scalone S, Marsico VA, Cardalesi C, Cognetti F, Salutari V, Attademo L, Guizzaro L, Schettino C, Piccirillo MC, Perrone F, Gallo C, Pignata S.

Gynecol Oncol. 2019 Jul;154(1):83-88. doi: 10.1016/j.ygyno.2019.04.012. Epub 2019 Apr 24.

PMID:
31029508
7.

A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?

Villani V, Fabi A, Tanzilli A, Pasqualetti F, Lombardi G, Vidiri A, Gonnelli A, Molinari A, Cantarella M, Bellu L, Terrenato I, Carosi M, Maschio M, Telera SM, Carapella CM, Cognetti F, Paiar F, Zagonel V, Pace A.

Future Oncol. 2019 May;15(15):1717-1727. doi: 10.2217/fon-2018-0826. Epub 2019 Apr 12.

PMID:
30977687
8.

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.

Verzoni E, Cartenì G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, Buti S, Rossetti S, Cognetti F, Rastelli F, Sobrero A, Turci D, Sternberg CN, Porta C, Cappuzzo F, Tortora G, Tassinari D, Panni S, Pazzola A, Surico G, Raimondi A, De Giorgi U, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program group.

J Immunother Cancer. 2019 Apr 3;7(1):99. doi: 10.1186/s40425-019-0579-z.

9.

PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?

Bazzichetto C, Conciatori F, Pallocca M, Falcone I, Fanciulli M, Cognetti F, Milella M, Ciuffreda L.

Cancers (Basel). 2019 Mar 28;11(4). pii: E435. doi: 10.3390/cancers11040435. Review.

10.

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.

Infante M, Fabi A, Cognetti F, Gorini S, Caprio M, Fabbri A.

J Exp Clin Cancer Res. 2019 Jan 8;38(1):12. doi: 10.1186/s13046-018-1001-2. Review.

11.

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.

Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V.

JAMA Oncol. 2019 Feb 1;5(2):187-194. doi: 10.1001/jamaoncol.2018.4514.

PMID:
30422243
12.

Role of mTOR Signaling in Tumor Microenvironment: An Overview.

Conciatori F, Bazzichetto C, Falcone I, Pilotto S, Bria E, Cognetti F, Milella M, Ciuffreda L.

Int J Mol Sci. 2018 Aug 19;19(8). pii: E2453. doi: 10.3390/ijms19082453. Review.

13.

T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer.

Fabi A, Alesini D, Valle E, Moscetti L, Caputo R, Caruso M, Carbognin L, Ciccarese M, La Verde N, Arpino G, Cannita K, Paris I, Santini D, Montemurro F, Russillo M, Ferretti G, Filippelli G, Rossello R, Fabbri A, Zambelli A, Leonardi V, D'Ottavio AM, Nisticò C, Stani S, Giampaglia M, Scandurra G, Catania G, Malaguti P, Giannarelli D, Cognetti F.

Breast. 2018 Oct;41:137-143. doi: 10.1016/j.breast.2018.07.004. Epub 2018 Jul 12.

PMID:
30092500
14.

Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?

Catania G, Malaguti P, Gasparro S, Cognetti F, Vidiri A, Fabi A.

Oncology. 2018;94 Suppl 1:29-33. doi: 10.1159/000489066. Epub 2018 Jul 24.

15.

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.

Del Curatolo A, Conciatori F, Cesta Incani U, Bazzichetto C, Falcone I, Corbo V, D'Agosto S, Eramo A, Sette G, Sperduti I, De Luca T, Marabese M, Shirasawa S, De Maria R, Scarpa A, Broggini M, Del Bufalo D, Cognetti F, Milella M, Ciuffreda L.

J Exp Clin Cancer Res. 2018 Jul 9;37(1):140. doi: 10.1186/s13046-018-0820-5.

16.

Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.

De Giorgi U, Cartenì G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, Bracarda S, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program Group.

BJU Int. 2019 Jan;123(1):98-105. doi: 10.1111/bju.14461. Epub 2018 Jul 23.

PMID:
29956884
17.

Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis.

Russillo M, Ferretti G, Vidiri A, Gasparro S, Cognetti F, Pellegrini D, Fabi A.

In Vivo. 2018 Jul-Aug;32(4):839-842. doi: 10.21873/invivo.11317.

18.

Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients.

Garassino MC, Gelibter AJ, Grossi F, Chiari R, Soto Parra H, Cascinu S, Cognetti F, Turci D, Blasi L, Bengala C, Mini E, Baldini E, Quadrini S, Ceresoli GL, Antonelli P, Vasile E, Pinto C, Fasola G, Galetta D, Macerelli M, Giannarelli D, Lo Russo G, de Marinis F.

J Thorac Oncol. 2018 Aug;13(8):1146-1155. doi: 10.1016/j.jtho.2018.04.025. Epub 2018 May 3.

19.

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators.

Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

PMID:
29482983
20.

mTOR Cross-Talk in Cancer and Potential for Combination Therapy.

Conciatori F, Ciuffreda L, Bazzichetto C, Falcone I, Pilotto S, Bria E, Cognetti F, Milella M.

Cancers (Basel). 2018 Jan 19;10(1). pii: E23. doi: 10.3390/cancers10010023. Review.

21.

Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?

Fabi A, Giannarelli D, Moscetti L, Santini D, Zambelli A, Laurentiis M, Caruso M, Generali D, Valle E, Leonardi V, Cannita K, Arpino G, Filippelli G, Ferretti G, Giampaglia M, Montemurro F, Nisticò C, Gasparro S, Cognetti F.

Future Oncol. 2017 Dec;13(30):2791-2797. doi: 10.2217/fon-2017-0336. Epub 2017 Nov 28.

PMID:
29182361
22.

Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study.

Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali D, Zambelli A, Scandurra G, Russillo M, Paris I, D'Ottavio AM, Filippelli G, Giampaglia M, Stani S, Fabbri A, Alesini D, Cianniello D, Giannarelli D, Cognetti F.

Oncotarget. 2017 Mar 18;8(38):64481-64489. doi: 10.18632/oncotarget.16373. eCollection 2017 Sep 8.

23.

Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer.

Ciuffreda L, Del Curatolo A, Falcone I, Conciatori F, Bazzichetto C, Cognetti F, Corbo V, Scarpa A, Milella M.

Ann Oncol. 2017 Nov 1;28(11):2896-2898. doi: 10.1093/annonc/mdx335. No abstract available.

PMID:
28666315
24.

The course of cancer related fatigue up to ten years in early breast cancer patients: What impact in clinical practice?

Fabi A, Falcicchio C, Giannarelli D, Maggi G, Cognetti F, Pugliese P.

Breast. 2017 Aug;34:44-52. doi: 10.1016/j.breast.2017.04.012. Epub 2017 May 11.

25.

Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.

Generali D, Montemurro F, Bordonaro R, Mafodda A, Romito S, Michelotti A, Piovano P, Ionta MT, Bighin C, Sartori D, Frassoldati A, Cazzaniga ME, Riccardi F, Testore F, Vici P, Barone CA, Schirone A, Piacentini F, Nolè F, Molino A, Latini L, Simoncini EL, Roila F, Cognetti F, Nuzzo F, Foglietta J, Minisini AM, Goffredo F, Portera G, Ascione G, Mariani G.

Oncologist. 2017 Jun;22(6):648-654. doi: 10.1634/theoncologist.2016-0461. Epub 2017 Apr 21.

26.

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.

Milella M, Falcone I, Conciatori F, Matteoni S, Sacconi A, De Luca T, Bazzichetto C, Corbo V, Simbolo M, Sperduti I, Benfante A, Del Curatolo A, Cesta Incani U, Malusa F, Eramo A, Sette G, Scarpa A, Konopleva M, Andreeff M, McCubrey JA, Blandino G, Todaro M, Stassi G, De Maria R, Cognetti F, Del Bufalo D, Ciuffreda L.

Sci Rep. 2017 Feb 21;7:43013. doi: 10.1038/srep43013.

27.

Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.

Lambertini M, Ceppi M, Cognetti F, Cavazzini G, De Laurentiis M, De Placido S, Michelotti A, Bisagni G, Durando A, Valle E, Scotto T, De Censi A, Turletti A, Benasso M, Barni S, Montemurro F, Puglisi F, Levaggi A, Giraudi S, Bighin C, Bruzzi P, Del Mastro L; MIG and GIM study groups.

Eur J Cancer. 2017 Jan;71:34-42. doi: 10.1016/j.ejca.2016.10.030. Epub 2016 Dec 10.

PMID:
27951450
28.

Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.

Giacinti S, Carlini P, Roberto M, Bassanelli M, Strigari L, Pavese F, Aschelter AM, Felici A, Valeriani M, Cognetti F, Marchetti P.

Anticancer Drugs. 2017 Jan;28(1):110-115.

PMID:
27763885
29.

Gender effects of single nucleotide polymorphisms and miRNAs targeting clock-genes in metastatic colorectal cancer patients (mCRC).

Garufi C, Giacomini E, Torsello A, Sperduti I, Melucci E, Mottolese M, Zeuli M, Ettorre GM, Ricciardi T, Cognetti F, Magnani M, Ruzzo A.

Sci Rep. 2016 Sep 26;6:34006. doi: 10.1038/srep34006.

30.

First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?

Fabi A, Malaguti P, Vari S, Cognetti F.

J Exp Clin Cancer Res. 2016 Jun 30;35:104. doi: 10.1186/s13046-016-0380-5. Review.

31.

Palbociclib: efficacious but predictive biomarkers still needed.

Cognetti F, Malaguti P, Alesini D.

Lancet Oncol. 2016 Apr;17(4):402-403. doi: 10.1016/S1470-2045(16)00144-3. Epub 2016 Mar 3. No abstract available.

PMID:
26947329
32.

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.

Fabi A, Giannarelli D, Malaguti P, Ferretti G, Vari S, Papaldo P, Nisticò C, Caterino M, De Vita R, Mottolese M, Iacorossi L, Cognetti F.

Drug Des Devel Ther. 2015 Nov 20;9:6177-83. doi: 10.2147/DDDT.S89575. eCollection 2015.

33.

Metastatic pancreatic cancer: Is there a light at the end of the tunnel?

Vaccaro V, Sperduti I, Vari S, Bria E, Melisi D, Garufi C, Nuzzo C, Scarpa A, Tortora G, Cognetti F, Reni M, Milella M.

World J Gastroenterol. 2015 Apr 28;21(16):4788-801. doi: 10.3748/wjg.v21.i16.4788. Review.

34.

PTEN: Multiple Functions in Human Malignant Tumors.

Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S, Cognetti F, Ciuffreda L.

Front Oncol. 2015 Feb 16;5:24. doi: 10.3389/fonc.2015.00024. eCollection 2015. Review.

35.

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.

Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators.

Lancet. 2015 May 9;385(9980):1863-72. doi: 10.1016/S0140-6736(14)62048-1. Epub 2015 Mar 2.

PMID:
25740286
36.

Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.

Fabi A, Moscetti L, Ciccarese M, Caramanti M, Salesi N, La Verde N, Russillo M, Generali D, Scandurra G, Vari S, Pacetti U, Cognetti F, Giannarelli D.

Future Oncol. 2015;11(3):431-8. doi: 10.2217/fon.14.271.

PMID:
25675124
37.

Nivolumab in previously untreated melanoma without BRAF mutation.

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA.

N Engl J Med. 2015 Jan 22;372(4):320-30. doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16.

38.

Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer.

Bria E, Di Modugno F, Sperduti I, Iapicca P, Visca P, Alessandrini G, Antoniani B, Pilotto S, Ludovini V, Vannucci J, Bellezza G, Sidoni A, Tortora G, Radisky DC, Crinò L, Cognetti F, Facciolo F, Mottolese M, Milella M, Nisticò P.

Oncotarget. 2014 Nov 30;5(22):11054-63.

39.

Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis.

Bria E, Massari F, Maines F, Pilotto S, Bonomi M, Porta C, Bracarda S, Heng D, Santini D, Sperduti I, Giannarelli D, Cognetti F, Tortora G, Milella M.

Crit Rev Oncol Hematol. 2015 Jan;93(1):50-9. doi: 10.1016/j.critrevonc.2014.08.001. Epub 2014 Aug 18. Review.

PMID:
25195095
40.

PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting.

Ciuffreda L, Falcone I, Incani UC, Del Curatolo A, Conciatori F, Matteoni S, Vari S, Vaccaro V, Cognetti F, Milella M.

Adv Biol Regul. 2014 Sep;56:66-80. doi: 10.1016/j.jbior.2014.07.002. Epub 2014 Jul 19. Review.

PMID:
25088603
41.

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.

Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, Del Vecchio M, Di Guardo L, Marchetti P, Ridolfi R, Cognetti F, Testori A, Bernengo MG, Guida M, Marconcini R, Mandalà M, Cimminiello C, Rinaldi G, Aglietta M, Queirolo P.

J Transl Med. 2014 May 7;12:116. doi: 10.1186/1479-5876-12-116.

42.

Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.

Vaccaro V, Fabi A, Vidiri A, Giannarelli D, Metro G, Telera S, Vari S, Piludu F, Carosi MA, Villani V, Cognetti F, Pompili A, Marucci L, Carapella CM, Pace A.

Biomed Res Int. 2014;2014:351252. doi: 10.1155/2014/351252. Epub 2014 May 4.

43.

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases.

Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A, Del Vecchio M, Di Guardo L, Maio M, Di Giacomo AM, Antonuzzo A, Cognetti F, Ferraresi V, Ridolfi L, Guidoboni M, Guida M, Pigozzo J, Chiarion Sileni V.

J Neurooncol. 2014 May;118(1):109-16. doi: 10.1007/s11060-014-1400-y. Epub 2014 Feb 16.

44.

Targeting bone metastatic cancer: Role of the mTOR pathway.

Bertoldo F, Silvestris F, Ibrahim T, Cognetti F, Generali D, Ripamonti CI, Amadori D, Colleoni MA, Conte P, Del Mastro L, De Placido S, Ortega C, Santini D.

Biochim Biophys Acta. 2014 Apr;1845(2):248-54. doi: 10.1016/j.bbcan.2014.01.009. Epub 2014 Feb 5. Review.

PMID:
24508774
45.

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.

Ascierto PA, Simeone E, Sileni VC, Del Vecchio M, Marchetti P, Cappellini GC, Ridolfi R, de Rosa F, Cognetti F, Ferraresi V, Testori A, Queirolo P, Bernengo MG, Guida M, Galli L, Mandalà M, Cimminiello C, Rinaldi G, Carnevale-Schianca F, Maio M.

Cancer Invest. 2014 May;32(4):144-9. doi: 10.3109/07357907.2014.885984. Epub 2014 Jan 31.

PMID:
24484235
46.

KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting.

Barone C, Pinto C, Normanno N, Capussotti L, Cognetti F, Falcone A, Mantovani L.

PLoS One. 2014 Jan 20;9(1):e85897. doi: 10.1371/journal.pone.0085897. eCollection 2014.

47.

Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC.

Ciuffreda L, Incani UC, Steelman LS, Abrams SL, Falcone I, Curatolo AD, Chappell WH, Franklin RA, Vari S, Cognetti F, McCubrey JA, Milella M.

Curr Pharm Des. 2014;20(24):3944-57. Review.

PMID:
24138714
48.

Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.

Vari S, Pilotto S, Maugeri-Saccà M, Ciuffreda L, Cesta Incani U, Falcone I, Del Curatolo A, Ceribelli A, Gelibter A, De Maria R, Tortora G, Cognetti F, Bria E, Milella M.

Expert Opin Drug Discov. 2013 Nov;8(11):1381-97. doi: 10.1517/17460441.2013.843523. Epub 2013 Oct 3. Review.

PMID:
24088065
49.

Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.

Cardillo I, Spugnini EP, Galluzzo P, Contestabile M, Dell'Anna ML, Picardo M, Crispi S, Calogero RA, Piccolo MT, Arigoni M, Cantarella D, Boccellino M, Quagliuolo L, Ferretti G, Carlini P, Felici A, Boccardo F, Cognetti F, Baldi A.

Future Oncol. 2013 Sep;9(9):1375-88. doi: 10.2217/fon.13.99.

PMID:
23980684
50.

Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility study.

Clavarezza M, Bordonaro R, Daniele B, Ferrandina G, Barni S, Turazza M, Coati F, De Matteis A, De Placido S, Cognetti F, Olmeo NA, Carrozza F, Bruzzi P, Del Mastro L; Gruppo Italiano Mammella.

Oncologist. 2013;18(8):924-5. doi: 10.1634/theoncologist.2013-0222. Epub 2013 Aug 12. Erratum in: Oncologist. 2013;18(10):1149.

Supplemental Content

Loading ...
Support Center